Simultaneous up-dosing of bee and vespid venom immunotherapy is safe
To the editor, Venom immunotherapy (VIT) is generally safe and prevents almost all patients from further systemic sting reactions. In recent studies, objective systemic adverse events (AE) were reported in 2.7 to 17.8% of patients. [1] [2] [3] It is well known that systemic AEs occur more frequently during the up-dosing phase of bee VIT compared with vespid VIT. 1, 4, 5 However, the rate of AEs was usually analyzed in mono-venom immunotherapy or in stepwise dual immunotherapy Ninety-two patients were treated with bee venom, 435 with vespid venom, and 123 simultaneously with bee and vespid venom; the rate of systemic AEs was 10.9%, 6.4%, and 10.6%, respectively. Some of the patients experienced more than one systemic AE (see Table 1 for further demographic data and Online Table S1 for demographic data listed separately for each up-dosing protocol). All systemic AEs, except one, occurred when administering 20 µg or more of therapeutic venom, most of them at 50 µg or more. There were three grade III reactions, with one reaction in each treatment group: syncope (vespid and bee VIT), nausea, and emesis (vespid VIT) or tachycardia, angioedema, and bronchospasm (bee VIT); all other patients had milder reactions.
The rate of AE during simultaneous VIT was almost identical with that of bee VIT (P = 1.000). Both groups did not differ significantly in age, sex, concomitant antihypertensive medication (either angiotensin-converting enzyme (ACE)-inhibitors, beta blockers, and/or angiotensin receptor blockers (ARB)), up-dosing protocol, grade of initial systemic sting reaction, tryptase levels, and grade of the systemic AE (see Table 1 ). Compared to bee VIT and simultaneous VIT, systemic AEs were less frequent during vespid VIT, although this was not statistically significant (P = .164). The frequency of large local reactions (LLR) at the injection site was similar in patients treated with bee, vespid, and both venoms, with slightly more LLR in patients with dual VIT (10.9%, 11.0%, and 14.6%, respectively). However, the difference was not statistically significant (P = .530).
In conclusion, no differences regarding systemic AE and LLR between mono-VIT and dual VIT could be found in this retrospective data analysis. Furthermore, the rate of systemic AEs in our mono-VIT groups did not differ from previous published data. [1] [2] [3] Although the number of included patients with dual VIT is limited, our data suggest that systemic and local AEs are not more frequently seen in patients simultaneously receiving bee and wasp venoms. For prospective studies, two methodological approaches are possible: (a) a non-inferiority approach with one-sided testing to demonstrate that dual VIT does not cause more side effects, or (b) a randomized trial comparing patients with simultaneously injected venoms and stepwise dual immunotherapy. For both approaches, multi-center studies with a large number of patients are required.
Taken together, our data indicate that simultaneous VIT is safe and timesaving and may therefore be another step to enhance patient adherence. However, prospective multi-center studies with sample size estimation and larger patient numbers are needed for future guidelines.
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